Sonnet BioTherapeutics (NASDAQ:SONN – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($1.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($11.12) by $9.56, Zacks reports. The business had revenue of $1,000 billion for the quarter.
Sonnet BioTherapeutics Stock Performance
NASDAQ SONN traded up $0.05 during trading on Friday, hitting $1.59. 47,330 shares of the company’s stock traded hands, compared to its average volume of 175,227. The stock has a fifty day moving average of $1.64 and a two-hundred day moving average of $2.25. Sonnet BioTherapeutics has a 12-month low of $1.41 and a 12-month high of $18.72.
Analyst Ratings Changes
Separately, Chardan Capital cut their price target on shares of Sonnet BioTherapeutics from $30.00 to $20.00 and set a “buy” rating for the company in a research report on Friday, December 20th.
Sonnet BioTherapeutics Company Profile
Sonnet BioTherapeutics Holdings, Inc, a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.
Read More
- Five stocks we like better than Sonnet BioTherapeutics
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Roblox’s Big Dip: A Chance to Get in on the Vaunted Gaming Stock?
- 3 Fintech Stocks With Good 2021 Prospects
- 3 Dividend ETFs to Capitalize on the Slide in Chip Stocks
- 3 Dividend Kings To Consider
- Is Chevron Stock Primed for Growth After Profit-Boosting News?
Receive News & Ratings for Sonnet BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonnet BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
